array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(28) "Bristol-Myers Squibb Company"
["slug"]=>
string(37) "81631-us-bristol-myers-squibb-company"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13"
["description"]=>
string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html"
["address_street"]=>
string(19) "430 E 29TH St FL 14"
["address_place"]=>
string(8) "New York"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1887-02-28"
["website_domain"]=>
string(7) "bms.com"
["website_url"]=>
string(19) "https://www.bms.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(1200)
["article_count"]=>
int(2495)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(37) "Bristol-Myers Squibb reports dividend"
["snippet_en"]=>
string(76) "Bristol-Myers Squibb Reports Dividend - News Details | Munich Stock Exchange"
["url"]=>
string(90) "https://www.boerse-muenchen.de/news/MyDividends67591/Bristol-Myers-Squibb-meldet-Dividende"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/d6f43487-4a33-4017-86d7-dfa9fc8b7a32"
["source"]=>
string(18) "boerse-muenchen.de"
["publication_date"]=>
string(10) "2023-09-21"
["categories"]=>
array(2) {
[0]=>
string(12) "Going Public"
[1]=>
string(12) "Stock Market"
}
}
[1]=>
array(7) {
["title_en"]=>
string(128) "S&P 500 stock Bristol-Myers Squibb stock: This is how much return an early investment in Bristol-Myers Squibb would have yielded"
["snippet_en"]=>
string(95) "That's how much gain an early buy into Bristol-Myers Squibb stock would have brought investors."
["url"]=>
string(174) "https://www.finanzen.ch/nachrichten/aktien/s-p-500-titel-bristol-myers-squibb-aktie-so-viel-gewinn-haette-ein-fruehes-investment-in-bristol-myers-squibb-abgeworfen-1032555525"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/0cadbea6-a871-435e-b5d2-fec52c5dd2c6"
["source"]=>
string(11) "finanzen.ch"
["publication_date"]=>
string(10) "2023-08-15"
["categories"]=>
array(4) {
[0]=>
string(18) "General Investment"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(12) "Going Public"
[3]=>
string(12) "Stock Market"
}
}
[2]=>
array(7) {
["title_en"]=>
string(61) "IPO Launch: Nurix Therapeutics Proposes $150 Million U.S. IPO"
["snippet_en"]=>
string(73) "The company is developing drug candidates to treat various blood cancers."
["url"]=>
string(64) "https://www.thestreet.com/ipo/news/nurix-therapeutics-ipo-launch"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/432ca051-fc16-4834-a637-385511b72bf3"
["source"]=>
string(13) "thestreet.com"
["publication_date"]=>
string(10) "2020-07-20"
["categories"]=>
array(4) {
[0]=>
string(18) "General Investment"
[1]=>
string(19) "Investment Requests"
[2]=>
string(12) "Going Public"
[3]=>
string(15) "Blogs & Columns"
}
}
[3]=>
array(7) {
["title_en"]=>
string(50) "IPO Preview: Nurix Therapeutics Starts IPO Process"
["snippet_en"]=>
string(247) "IPO Preview: Nurix Therapeutics Starts IPO Process
IPOStreet
4 hours ago
Nurix Therapeutics (NRIX) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing small molecule-based"
["url"]=>
string(57) "https://www.thestreet.com/ipo/news/nurix-therapeutics-ipo"
["image_url"]=>
NULL
["source"]=>
string(13) "thestreet.com"
["publication_date"]=>
string(10) "2020-07-08"
["categories"]=>
array(4) {
[0]=>
string(18) "General Investment"
[1]=>
string(19) "Investment Requests"
[2]=>
string(12) "Going Public"
[3]=>
string(15) "Blogs & Columns"
}
}
[4]=>
array(7) {
["title_en"]=>
string(35) "Mead Johnson IPO off to sweet start"
["snippet_en"]=>
string(159) "Investors welcome the $720 million stock debut from infant-formula maker Mead Johnson, driving shares in the enlarged initial public offering as much as 13%..."
["url"]=>
string(66) "https://marketwatch.com/story/mead-johnson-rallies-first-ipo-since"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a2e11d9d-7dcb-4cd5-9553-95955e5c2352"
["source"]=>
string(15) "marketwatch.com"
["publication_date"]=>
string(10) "2020-06-10"
["categories"]=>
array(1) {
[0]=>
string(12) "Going Public"
}
}
[5]=>
array(7) {
["title_en"]=>
string(53) "IPO Preview: Repare Therapeutics Starts U.S. IPO Plan"
["snippet_en"]=>
string(116) "RPTX has a promising collaboration with Bristol-Myers Squibb to use its SNIPRx platform for drug discovery purposes."
["url"]=>
string(58) "https://www.thestreet.com/ipo/news/repare-therapeutics-ipo"
["image_url"]=>
NULL
["source"]=>
string(13) "thestreet.com"
["publication_date"]=>
string(10) "2020-06-08"
["categories"]=>
array(3) {
[0]=>
string(14) "Product Launch"
[1]=>
string(12) "Going Public"
[2]=>
string(13) "Collaboration"
}
}
[6]=>
array(7) {
["title_en"]=>
string(56) "An All-or-Nothing Bet on 3 Drugs in Celgene’s Pipeline"
["snippet_en"]=>
string(127) "Soon to start trading on the New York Stock Exchange, the Bristol-Myers CVR amounts to a lottery ticket on three Celgene drugs."
["url"]=>
string(117) "https://www.barrons.com/articles/with-bristol-myers-cvr-investors-can-bet-on-3-drugs-in-celgenes-pipeline-51574269284"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/49d80b28-1af9-499b-a0f9-016c599eb43c"
["source"]=>
string(11) "barrons.com"
["publication_date"]=>
string(10) "2019-11-20"
["categories"]=>
array(3) {
[0]=>
string(12) "Going Public"
[1]=>
string(6) "Merger"
[2]=>
string(12) "Stock Market"
}
}
[7]=>
array(7) {
["title_en"]=>
string(56) "Bristol-Myers Squibb Earnings: BMY Stock Pops on Q1 Beat"
["snippet_en"]=>
string(280) "InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Bristol-Myers Squibb earnings for the first quarter of 2019 have BMY stock up on Thursday. Source: A 4 via Flickr. Bristol-Myers Squibb (NYSE: BMY ) reported earnings per share of $1.10 for the first quarter of 2019."
["url"]=>
string(96) "https://www.nasdaq.com/article/bristol-myers-squibb-earnings-bmy-stock-pops-on-q1-beat-cm1136047"
["image_url"]=>
NULL
["source"]=>
string(10) "nasdaq.com"
["publication_date"]=>
string(10) "2019-04-25"
["categories"]=>
array(3) {
[0]=>
string(12) "Going Public"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(12) "Stock Market"
}
}
[8]=>
array(7) {
["title_en"]=>
string(55) "Mead Johnson to spin off from Bristol-Myers through IPO"
["snippet_en"]=>
string(155) "SAN FRANCISCO (MarketWatch) -- Mead Johnson Nutrition, a unit of Bristol-Myers Squibb undefined, will separate from the drug giant via an initial public..."
["url"]=>
string(85) "https://marketwatch.com/story/mead-johnson-to-spin-off-from-bristol-myers-through-ipo"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/22251797-4f77-4da5-9f8d-9d2fb1f24ce0"
["source"]=>
string(15) "marketwatch.com"
["publication_date"]=>
string(10) "2018-09-06"
["categories"]=>
array(1) {
[0]=>
string(12) "Going Public"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(254)
}
[1]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(163)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(151)
}
[3]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(94)
}
[4]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(89)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(76)
}
[6]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(74)
}
[7]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(64)
}
[8]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(63)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(60)
}
[10]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(60)
}
[11]=>
array(2) {
["name"]=>
string(17) "Energy Management"
["count"]=>
int(56)
}
[12]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(54)
}
[13]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(47)
}
[14]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(47)
}
[15]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(45)
}
[16]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(45)
}
[17]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(42)
}
[18]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(39)
}
[19]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(35)
}
[20]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[21]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(33)
}
[22]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(32)
}
[23]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(28)
}
[24]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(22)
}
[28]=>
array(2) {
["name"]=>
string(9) "Valuation"
["count"]=>
int(21)
}
[29]=>
array(2) {
["name"]=>
string(15) "Blogs & Columns"
["count"]=>
int(21)
}
}
}
81631-us-bristol-myers-squibb-company
Bristol-Myers Squibb Company
Location
New York
Founded
1887-02-28
Website
https://www.bms.com
Articles
2495 Articles
Category
Pharmaceutical Preparations
Description
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
IPO Preview: Nurix Therapeutics Starts IPO Process
IPOStreet
4 hours ago
Nurix Therapeutics (NRIX) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing small molecule-based
Investors welcome the $720 million stock debut from infant-formula maker Mead Johnson, driving shares in the enlarged initial public offering as much as 13%...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Bristol-Myers Squibb earnings for the first quarter of 2019 have BMY stock up on Thursday. Source: A 4 via Flickr. Bristol-Myers Squibb (NYSE: BMY ) reported earnings per share of $1.10 for the first quarter of 2019.
SAN FRANCISCO (MarketWatch) -- Mead Johnson Nutrition, a unit of Bristol-Myers Squibb undefined, will separate from the drug giant via an initial public...
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
